Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Kan Chen

Partner

Liwen Chen

Associate

Nan Chen

Principal

David Chu

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Associate

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho Ph.D

Venture Partner

William Hu

Managing Partner

Duane Kuang

Founding Managing Partner

Nisa Leung

Managing Partner

Lisa Li

Investor

Dingzheng Li

Vice President

Jing Liu

Associate

Chang Liu

Associate

Bin Liu

Associate

Biao Lu

Associate

Shuo Mao

Principal

Will Mcconnell

Principal

Mark McDade

Co-Founder and Managing Partner

Gary Rieschel

Founder and Managing Partner

Motao Sun

Associate

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Rachel Wang

Venture Partner

Xin Wang

Investor

James Wang

Venture Partner

Gillian Xu

RMB funds CFO

Kuantai Yeh

Partner

Peter (Ming) Yin

Principal, Cleantech

Janet Yu Ph.D

Partner

Liang Yuyu

Managing Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Managing Partner

Zhiyuan Zhou

Investor

Zhifeng Zhou

Managing Partner

Yiqing Zhu

Associate

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

Past deals in Health Diagnostics

Hochuen Medical

Series B in 2023
Hochuen Medical, founded in 2015 by Dr. Robin Liu and Eric Zeng, specializes in contract development and manufacturing, focusing on microfluidic chips and biomedical consumables. The company leverages the extensive management experience of its founders, who have over 20 years in the fields of in vitro diagnostics (IVD), microfluidics, and electronics manufacturing. Hochuen Medical produces a range of in vitro diagnostic products, including microfluidic biochips, disposable consumables for IVD, point-of-care testing kits, life science research consumables, gene sequencing chips, and detection cards for animal, plant, and food safety testing. The company is committed to providing clients with high-quality, end-to-end contract manufacturing solutions, drawing on its expertise in research and production management.

Soda Health

Series A in 2022
Soda Health is a healthcare technology company dedicated to addressing health inequities and promoting a healthier America. The company offers a technology platform designed to help individuals identify, access, and pay for essential resources that support their health and well-being. By providing personalized benefits and streamlining the reimbursement process, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, making healthcare more accessible and affordable.

Biotree

Series A in 2022
Shanghai Biotree Biotech Co., Ltd. specializes in the development and application of life science research technologies. Founded in 2013, the company is based in Shanghai, China, and focuses on sample testing, big data analysis, and technical product development within the life sciences sector. It offers a range of professional services tailored to universities, research institutes, hospitals, and enterprises. Biotree is particularly noted for its expertise in metabolomics, providing early detection and analysis services, as well as consulting related to mass spectrometry and metabolic testing. The company has a strong portfolio of patents in metabolomics and continues to innovate in product development and technology within this field. Since its inception, Biotree has demonstrated consistent growth and profitability, establishing itself as a key player in the domestic metabolomics detection and analysis market.

Gaugene

Series B in 2022
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

InSilico Medicine

Series D in 2022
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Ashermed

Series B in 2022
Developer of contract research organization (CRO) platform for medical companies. The company focuses on the integration of CRO with Internet technology, big data, artificial intelligence and other advanced technologies, enabling medical companies to shorten the drug development cycle, improve the quality of clinical data and reduce research and development costs.

Prime Lifescience

Seed Round in 2022
Prime Lifescience is a developer of a big data platform tailored for the life sciences sector. The company focuses on creating a health lifecycle big data collaboration network through innovative digital technologies and the application of artificial intelligence. Prime Lifescience offers a range of services, including a digital smart health community, a digital intelligent clinical research accelerator, and a live big data platform. These offerings aim to enhance digital clinical research and foster a comprehensive medical solutions framework within the healthcare industry, leveraging extensive data to improve health outcomes.

Wowjoy Technology

Series A in 2022
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

CureGenetics

Series B in 2022
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Shanzhen

Series D in 2021
Shanzhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups and personalized health management plans, alongside insurance options. Additionally, Shanzhen offers a range of medical examination services and data finance products aimed at tackling the challenges posed by an aging population and the rising incidence of chronic diseases. By prioritizing the well-being of elderly patients, Shanzhen aims to enhance their quality of life, enabling them to lead happier and healthier lives.

Zeen Health

Venture Round in 2021
Zeen Health is a digital therapeutics company that provides mental health services. Zeen Health was founded in 2019 and was headquartered in Shenzhen, China.

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Pluslife

Series A in 2021
PlusLife Biotech is devoted to developing revolutionary molecular diagnostic tools and gene treatment programs employing a new generation of gene technology. Founded in 2017 and is based in Guangzhou, China.

Wowjoy Technology

Series A in 2021
Wowjoy Technology develops a platform to provide data-driven medical services. The firm is headquartered in Hangzhou, China.

Lingyi Zhihui

Series B in 2021
Zuoshouyisheng's AI ​​doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.

Soda Health

Seed Round in 2021
Soda Health is a healthcare technology company dedicated to addressing health inequities and promoting a healthier America. The company offers a technology platform designed to help individuals identify, access, and pay for essential resources that support their health and well-being. By providing personalized benefits and streamlining the reimbursement process, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, making healthcare more accessible and affordable.

Berry Oncology

Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Hochuen Medical

Series A in 2021
Hochuen Medical, founded in 2015 by Dr. Robin Liu and Eric Zeng, specializes in contract development and manufacturing, focusing on microfluidic chips and biomedical consumables. The company leverages the extensive management experience of its founders, who have over 20 years in the fields of in vitro diagnostics (IVD), microfluidics, and electronics manufacturing. Hochuen Medical produces a range of in vitro diagnostic products, including microfluidic biochips, disposable consumables for IVD, point-of-care testing kits, life science research consumables, gene sequencing chips, and detection cards for animal, plant, and food safety testing. The company is committed to providing clients with high-quality, end-to-end contract manufacturing solutions, drawing on its expertise in research and production management.

Insight Lifetech

Series D in 2021
Insight Lifetech Co., Ltd. is a Chinese company focused on the development and manufacturing of medical equipment for heart intervention. The firm specializes in creating high-quality devices designed to enhance the diagnosis and therapy of cardiovascular diseases. By utilizing innovative technologies, Insight Lifetech aims to provide reliable precision in medical treatments, ultimately enabling healthcare professionals to save and improve patients' lives.

InSilico Medicine

Series C in 2021
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

LetsGetChecked

Series D in 2021
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

BrainHealth

Series C in 2021
Developer of Tumor-treating Fields technology. The company's products are focused on delivering diagnostic and minimally invasive treatment tools for various brain cancers, enabling healthcare professionals to more effectively treat patients.

Insight Lifetech

Secondary Market in 2021
Insight Lifetech Co., Ltd. is a Chinese company focused on the development and manufacturing of medical equipment for heart intervention. The firm specializes in creating high-quality devices designed to enhance the diagnosis and therapy of cardiovascular diseases. By utilizing innovative technologies, Insight Lifetech aims to provide reliable precision in medical treatments, ultimately enabling healthcare professionals to save and improve patients' lives.

Health Biotech

Series B in 2021
Beijing Health Biotech Co. Ltd. specializes in the development of diagnostic and therapeutic products aimed at the diagnosis, treatment, and monitoring of Alzheimer's disease. Founded in 2016 and based in Beijing, the company employs advanced mass spectrometry technology, specifically liquid chromatography-mass spectrometry, to facilitate early diagnosis and treatment. Its product offerings include a range of diagnostic tests for various conditions, including Alzheimer's disease, cardiovascular disease, and genetic metabolic disorders. In addition, the company provides therapeutic drug monitoring, neonatal genetic metabolic disease screening, and clinical testing services. Through its innovations, Health Biotech seeks to aid healthcare professionals in enhancing patient outcomes, particularly in improving cognitive abilities and delaying the onset of Alzheimer's disease.

Hope Medicine

Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

SinoUnited Health

Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

Gaugene

Series A in 2021
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

ET Healthcare

Series G in 2021
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

Fucunbao

Series C in 2021
Developer and operator of an online insurance and medical portal platform intended to serve the rural communities in China. The company's platform allows users to pay for insurance online, create reimbursement plans, and identify disease types online, providing easy access to insurance and online medical services for rural communities in China. The company utilizes government funding and resources to subsidize insurance and medical bills, alleviating poverty caused by medical challenges in rural communities.

Delta Medical

Series E in 2021
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Miaoshou Doctor

Series E in 2021
Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Insight Lifetech

Series C in 2020
Insight Lifetech Co., Ltd. is a Chinese company focused on the development and manufacturing of medical equipment for heart intervention. The firm specializes in creating high-quality devices designed to enhance the diagnosis and therapy of cardiovascular diseases. By utilizing innovative technologies, Insight Lifetech aims to provide reliable precision in medical treatments, ultimately enabling healthcare professionals to save and improve patients' lives.

Microtech Medical

Series D in 2020
MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

dMed

Series C in 2020
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Broncus Medical

Series C in 2020
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).

Delta Medical

Series D in 2020
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

Shukun

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.

New Horizon Health

Series E in 2020
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Shukun

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.

Miaoshou Doctor

Series D in 2020
Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Alamar Biosciences

Series A in 2020
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Microtech Medical

Venture Round in 2020
MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Belief Biomed

Debt Financing in 2020
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

New Horizon Health

Series D in 2020
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Shulan Health

Series C in 2020
Shulan Hospital is a hospital center that provides rehabilitation, nutrition, health examination, and remote-consultation services.

Bioscience

Venture Round in 2020
Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.

CureGenetics

Series A in 2020
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Berry Oncology

Series A in 2020
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Berry Genomics

Post in 2020
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Element Science

Series C in 2020
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

Yuanxin Huibao

Series A in 2019
Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.

SinoUnited Health

Series C in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

dMed

Series B in 2019
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Tisenc

Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., founded in 2015 and based in Shenzhen, China, specializes in the development, manufacture, and global sales of chemiluminescence immunology (CLIA) systems. The company focuses on producing advanced medical testing solutions, including point-of-care testing systems, diagnostic reagents, and molecular diagnostics solutions. Tisenc operates from a facility that encompasses over 16,000 square meters, featuring research and development laboratories, a GMP factory, and an instrument manufacturing site. The company holds full intellectual property rights for its products and technologies, allowing for independent research and development as well as production capabilities. Tisenc aims to provide innovative technological support to medical practitioners through its automatic chemiluminescent analyzers and diagnostic reagents, enhancing the field of medical diagnostics.

Shanzhen

Series D in 2019
Shanzhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups and personalized health management plans, alongside insurance options. Additionally, Shanzhen offers a range of medical examination services and data finance products aimed at tackling the challenges posed by an aging population and the rising incidence of chronic diseases. By prioritizing the well-being of elderly patients, Shanzhen aims to enhance their quality of life, enabling them to lead happier and healthier lives.

Huimei Technology

Series C in 2019
Huimei Technology develops and designs medical artificial intelligence solutions that focus on improving clinical quality. Core products - "single disease process quality management system", "Clinical Decision Support System (CDSS)" integrated evidence-based medical knowledge base, using natural language processing, deep learning and other AI techniques to process clinical big data, emergency department, hospitalization Link real-time assistance to doctors in decision-making, the advantage is to integrate the standard electronic clinical path and workflow, assist clinicians to make more personalized and effective diagnosis and treatment decisions according to the patient's condition, and promote products to the outpatient, emergency, and ward of large hospitals. application.

Delta Medical

Series C in 2019
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

MyHealthTeams

Series B in 2019
MyHealthTeams, Inc. is a San Francisco-based company that creates online social networking platforms for individuals living with chronic health conditions and those who care for them. Founded in 2011, the company operates various platforms, including MyAutismTeam, MyBCTeam, MyMSTeam, and MyCrohnsandColitisTeam, designed to foster connections among users who share similar health challenges. By facilitating these connections, MyHealthTeams enhances patient engagement, allowing users to find support and share experiences with others who understand their daily struggles. The company has developed over 30 distinct social networks, serving approximately 90% of the chronic condition population across 13 countries.

APT Medical

Venture Round in 2019
APT Medical Inc. is a high-tech enterprise focused on the research, development, manufacture, and sale of minimally invasive interventional medical devices targeting cardiovascular and cerebrovascular diseases. The company offers a range of products, including electrophysiological catheter delivery systems, radiofrequency ablation and mapping catheters, as well as various vascular intervention products and accessories. APT Medical also provides OEM and ODM services for catheter and metal products. Founded in 2002 and headquartered in Shenzhen, China, the company operates production facilities in Guanlan, Shenzhen, and Xiangxiang, Hunan, and markets its products across Europe, Eastern Europe, Southeast Asia, and other regions worldwide.

Bondent Technology

Series D in 2019
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

Yuanxin Huibao

Series A in 2019
Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.

ZD Medical

Series A in 2019
ZD Medical is a medical device company that specializes in the development of innovative optical coherence tomography angiography devices. The company focuses on advancing medical imaging technology to assist healthcare professionals in identifying internal patient symptoms. By concentrating on venous medical imaging and optical imaging technology, ZD Medical aims to enhance the capabilities of healthcare providers, ultimately improving patient treatment outcomes.

New Horizon Health

Series C in 2019
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

SinoUnited Health

Series B in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

LetsGetChecked

Series B in 2019
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Anxin Doctor

Series B in 2019
Anxin Doctor is a mobile healthcare platform focused on maternal and pediatric health. It connects patients with obstetricians, gynecologists, and pediatricians through its application, which facilitates access to healthcare advice and clinical appointment bookings. By bridging the gap between patients and healthcare professionals, Anxin Doctor aims to enhance health outcomes for mothers and children, ensuring timely and efficient medical care.

ACEA BIO

Venture Round in 2019
ACEA Biosciences, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of advanced microelectronic sensor systems for cell-based assays, drug discovery, and diagnostics. Founded in 2002, ACEA has pioneered real-time, label-free cell-based assay technology, marketed under the xCELLigence brand. Its product lineup includes the x-CELLigence System for various applications in biomedicine and pharmaceuticals, CIM systems for real-time monitoring of cell migration, and several RTCA instruments for cardiotoxicity testing and impedance measurement. The company serves a global customer base of over 800 clients and has contributed to more than 350 peer-reviewed publications. Additionally, ACEA has a Therapeutics Business Unit focusing on oncology drug discovery, leveraging its biosensor technology and a proprietary library of over one million compounds. Currently, ACEA has a program in phase II clinical trials in China, underlining its commitment to innovation in the research and healthcare sectors. The company operates manufacturing facilities in Hangzhou, China, and is a subsidiary of Agilent Technologies, Inc.

Microtech Medical

Series C in 2018
MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

APT Medical

Series C in 2018
APT Medical Inc. is a high-tech enterprise focused on the research, development, manufacture, and sale of minimally invasive interventional medical devices targeting cardiovascular and cerebrovascular diseases. The company offers a range of products, including electrophysiological catheter delivery systems, radiofrequency ablation and mapping catheters, as well as various vascular intervention products and accessories. APT Medical also provides OEM and ODM services for catheter and metal products. Founded in 2002 and headquartered in Shenzhen, China, the company operates production facilities in Guanlan, Shenzhen, and Xiangxiang, Hunan, and markets its products across Europe, Eastern Europe, Southeast Asia, and other regions worldwide.

Cardialen

Series B in 2018
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

DK Medtech

Series B in 2018
DK Medtech is a healthcare company based in Suzhou, China, specializing in the development and production of balloon catheter medical devices. Established in 2015, the company focuses on innovative solutions for medical applications, contributing to advancements in healthcare technology. Through its expertise in catheter design and manufacturing, DK Medtech aims to enhance patient outcomes and improve procedural efficiency in various medical settings.

ET Healthcare

Series C in 2018
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

MicroPoint Bioscience

Series E in 2018
MicroPoint Bioscience, Inc. (微点生物) is a Chinese company dedicated to biochip research and development. The company offers a product series, Lab On a Chip, which is based on micro-electronic mechanical technologies. MicroPoint Biosciences customizes demanded products and services for customers in areas of human health such as medicine, environmental protection, food safety, scientific research, and other application areas. In the area of medicine, MicroPoint Company's bedside immediate diagnosis chip and examination instrument provides low-cost resolutions for early diagnosis and the process monitoring of vascular diseases, tumors, emergency treatments, and operations.

CureGenetics

Series A in 2018
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

APT Medical

Series B in 2018
APT Medical Inc. is a high-tech enterprise focused on the research, development, manufacture, and sale of minimally invasive interventional medical devices targeting cardiovascular and cerebrovascular diseases. The company offers a range of products, including electrophysiological catheter delivery systems, radiofrequency ablation and mapping catheters, as well as various vascular intervention products and accessories. APT Medical also provides OEM and ODM services for catheter and metal products. Founded in 2002 and headquartered in Shenzhen, China, the company operates production facilities in Guanlan, Shenzhen, and Xiangxiang, Hunan, and markets its products across Europe, Eastern Europe, Southeast Asia, and other regions worldwide.

dMed

Series B in 2018
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Core Medical

Series A in 2018
Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.

Tisenc

Series A in 2018
Shenzhen Tisenc Medical Devices Co., Ltd., founded in 2015 and based in Shenzhen, China, specializes in the development, manufacture, and global sales of chemiluminescence immunology (CLIA) systems. The company focuses on producing advanced medical testing solutions, including point-of-care testing systems, diagnostic reagents, and molecular diagnostics solutions. Tisenc operates from a facility that encompasses over 16,000 square meters, featuring research and development laboratories, a GMP factory, and an instrument manufacturing site. The company holds full intellectual property rights for its products and technologies, allowing for independent research and development as well as production capabilities. Tisenc aims to provide innovative technological support to medical practitioners through its automatic chemiluminescent analyzers and diagnostic reagents, enhancing the field of medical diagnostics.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

Miaoshou Doctor

Series C in 2018
Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Bondent Technology

Series C in 2018
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

ZD Medical

Series A in 2018
ZD Medical is a medical device company that specializes in the development of innovative optical coherence tomography angiography devices. The company focuses on advancing medical imaging technology to assist healthcare professionals in identifying internal patient symptoms. By concentrating on venous medical imaging and optical imaging technology, ZD Medical aims to enhance the capabilities of healthcare providers, ultimately improving patient treatment outcomes.

LetsGetChecked

Series A in 2018
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Infervision

Series B in 2018
Infervision is an artificial intelligence company based in Beijing that specializes in enhancing medical imaging diagnosis through deep learning and computer vision technologies. The company focuses on developing clinically valuable products aimed at improving the accuracy and efficiency of cancer diagnosis. Infervision has introduced innovative solutions such as the world's first artificial intelligence precise healthcare platform, along with intelligent X-ray and CT diagnostic products, which are currently undergoing trials at several prominent hospitals in China. The company collaborates closely with top institutions in radiology, fostering a strong relationship between medical science and technology. Infervision has partnered with approximately 20 leading hospitals, successfully integrating medical data and technology to advance healthcare solutions. By creating a unique artificial intelligence computing platform, Infervision aims to facilitate precise healthcare and improve diagnostic outcomes for medical professionals.

Frontage Holdings

Venture Round in 2018
Frontage Holdings Corporation is a contract research organization that offers a range of research, analytical, and development services primarily to pharmaceutical, biotechnology, and agrochemical companies. Founded in 2018 and headquartered in Exton, Pennsylvania, Frontage supports drug discovery and development through services such as drug metabolism, pharmacokinetics, safety and toxicology, and bioanalytical testing. Additionally, the company provides comprehensive support for clinical studies, including early-stage clinical trials and biometrics, as well as product development and bioequivalence studies. Frontage operates in various regions, including the United States, Canada, China, Europe, India, Japan, Korea, Israel, and Australia, with a significant portion of its revenue generated from North America. As a subsidiary of Hong Kong Tigermed Co., Limited, Frontage plays a vital role in advancing research and development efforts for biopharmaceutical organizations, facilitating the submission of drug applications and enhancing the efficiency of the drug development process.

ACEA BIO

Series E in 2018
ACEA Biosciences, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of advanced microelectronic sensor systems for cell-based assays, drug discovery, and diagnostics. Founded in 2002, ACEA has pioneered real-time, label-free cell-based assay technology, marketed under the xCELLigence brand. Its product lineup includes the x-CELLigence System for various applications in biomedicine and pharmaceuticals, CIM systems for real-time monitoring of cell migration, and several RTCA instruments for cardiotoxicity testing and impedance measurement. The company serves a global customer base of over 800 clients and has contributed to more than 350 peer-reviewed publications. Additionally, ACEA has a Therapeutics Business Unit focusing on oncology drug discovery, leveraging its biosensor technology and a proprietary library of over one million compounds. Currently, ACEA has a program in phase II clinical trials in China, underlining its commitment to innovation in the research and healthcare sectors. The company operates manufacturing facilities in Hangzhou, China, and is a subsidiary of Agilent Technologies, Inc.

Innostic

Series A in 2018
Innostic distributes and supplies medical device consumable materials. The company is based in Beijing, China.

Berry Oncology

Series A in 2018
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

Berry Genomics

Funding Round in 2018
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.

Twine Health

Series A in 2017
Twine Health is a cloud-based collaborative care platform for chronic disease management. It consists of a patient engagement portal, a peer support network, a care management solution, and an outcome analytics tool. The platform enables users to co-create personalized care plans that serve as common ground for collaboration with their care team: their own providers such as physicians and nurse practitioners; their family and friends; and coaches such as nurses, pharmacists, health coaches, and more. Twine Health was developed at the MIT Medical Lab by John Moore and Frank Moss and its operations are based in Massachusetts, United States.

Bioscience

Series C in 2017
Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.